<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01088360</url>
  </required_header>
  <id_info>
    <org_study_id>IM101-045B</org_study_id>
    <nct_id>NCT01088360</nct_id>
  </id_info>
  <brief_title>Safety Study of Abatacept to Treat Rheumatoid Arthritis (B)</brief_title>
  <official_title>An Observational Cohort to Assess Safety and Outcomes in Patients Treated With Abatacept and Other Anti-Rheumatic Therapies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Data Bank for Rheumatic Diseases (NDB)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the incidence rates of targeted infections,
      malignancies and mortality among patients with rheumatoid arthritis who are treated with
      abatacept and those who are treated with other anti-rheumatic medications.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 31, 2005</start_date>
  <completion_date type="Anticipated">September 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Key safety outcomes (targeted infections, malignancies, mortality)</measure>
    <time_frame>Every 6 months throughout the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient-reported infusion reactions</measure>
    <time_frame>Every 6 months throughout the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple sclerosis, lupus, and psoriasis</measure>
    <time_frame>Every 6 months throughout the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events in pregnant women who receive abatacept</measure>
    <time_frame>Every 6 months throughout the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events in subjects on abatacept who receive concomitant biologics</measure>
    <time_frame>Every 6 months throughout the study</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">20000</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Patients with rheumatoid arthritis initiating abatacept</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Pts with RA initiating other biologic disease-modifying drugs</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Pts w/ RA non-biologic disease-modifying anti-rheumatic drugs</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients being treated for rheumatoid arthritis in the US
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  Diagnosis of rheumatoid arthritis

          -  &gt; 18 years at index treatment initiation or switch

          -  Starting treatment with abatacept or new disease-modifying anti-rheumatic drug
             (including switching or adding) or biologic disease modifying drug.

          -  Read/write English

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_inquiry_form.aspx</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2010</study_first_submitted>
  <study_first_submitted_qc>March 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2010</study_first_posted>
  <last_update_submitted>January 10, 2018</last_update_submitted>
  <last_update_submitted_qc>January 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abatacept</mesh_term>
    <mesh_term>Antirheumatic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

